Related Experiment Video
Updated: Jun 15, 2025
07:58
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
478
GluN2A: A Promising Target for Developing Novel Antidepressants
Gang Wang1, Wang Qi2, Qiu-Hua Liu1
1Department of Hepatobiliary Surgery, Zhangjiagang Hospital affiliated to Soochow University/The First People's Hospital of Zhangjiagang City, Zhangjiagang, China.
The International Journal of Neuropsychopharmacology
|August 26, 2024
Summary
Targeting the GluN2A N-methyl D-aspartate receptor (NMDAR) subunit offers a promising avenue for treating depression. Inhibiting GluN2A demonstrates resistance to stress-induced depressive behaviors, suggesting its therapeutic potential.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Depression is a complex mental health disorder with significant disability.
- N-methyl D-aspartate receptor (NMDAR) modulators are investigated for depression treatment.
- The role of the GluN2A NMDAR subunit in depression pathophysiology remains unclear.
Purpose of the Study:
- To elucidate the function of the GluN2A subunit in depression.
- To explore the link between GluN2A expression, neuroinflammation, and neurogenesis in depression pathogenesis.
Main Methods:
- Review of existing literature on GluN2A and depression.
- Summary of depression pathogenesis related to GluN2A expression regulation.
- Analysis of GluN2A's interaction with neuroinflammation and neurogenesis.
Main Results:
- Overexpression of GluN2A impairs synaptic plasticity, contributing to depression.
- Selective antagonists targeting GluN2A subunits are crucial for therapeutic development.
Conclusions:
- Specific inhibition of the GluN2A NMDAR subunit confers resistance to stress-induced depressive behaviors.
- Targeting GluN2A presents a promising strategy for novel antidepressant development.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
205
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
205
01:25Antidepressant Drugs: Overview
394
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
394
01:21G-protein Coupled Receptors
117.2K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
117.2K
01:15G Protein-coupled Receptors
11.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.6K
01:24Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
01:26Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K